PHAR

Pharming Group N.V.

• NASDAQ·6d ago

  Pharming's Leniolisib Shows Promise Beyond APDS In Rare Genetic Immune Disorders

• NASDAQ·6d ago

  Pharming Reports Positive Phase II Data For Leniolisib In Rare Genetic Immune Disorders

• Benzinga·6d ago

  Pharming Says Leniolisib Reduced Spleen Volume In 10 Of 11 Evaluable Participants And Lymph Node Size In All 4 In Phase II Genetic PID Trial, With No New Safety Signals

• TipRanks·09/30 13:15

  Pharming Group: Buy Rating Maintained and Strategy Intact Despite Surprise CEO Departure; Price Target Reaffirmed at $38

• Seeking Alpha·09/30 12:16

  Pharming Group: Viable Contrarian Buy If Ruconest Stabilizes

• TipRanks·09/30 11:50

  Analysts Are Bullish on These Healthcare Stocks: Pharming Group (PHAR), Inventiva (IVA)

• TipRanks·09/29 09:50

  Pharming announces CEO Fabrice Chouraqui to step down

• Seeking Alpha·09/29 09:39

  Pharming CEO Fabrice Chouraqui steps down

• Seeking Alpha·09/29 09:01

  Biggest stock movers Tuesday: SMMT, NVTS, and more

• NASDAQ·09/25 16:09

  FDA Accepts Pharming's SNDA For Lower-Dose Joenja In Children With APDS

• TipRanks·09/25 14:35

  Pharming announces FDA acceptance, Priority review of sNDA for Joenja

• TipRanks·09/23 11:16

  Canaccord Genuity Reaffirms Their Buy Rating on Pharming Group (PHAR)

• Dow Jones·09/22 16:26

  Pharming Group Price Target Maintained With a $37.00/Share by HC Wainwright & Co.

• Benzinga·09/22 16:16

  HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

• TipRanks·09/22 16:00

  Analysts’ Top Healthcare Picks: The Ensign Group (ENSG), Pharming Group (PHAR)